BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25267750)

  • 61. Sunitinib-induced hand-foot syndrome in a renal cell carcinoma: a sclerodermatous and rheumatoid arthritis-like case.
    Ohtsuka T
    J Dermatol; 2012 Nov; 39(11):943-4. PubMed ID: 22257303
    [No Abstract]   [Full Text] [Related]  

  • 62. Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies.
    Alexandrescu DT; Popoveniuc G; Farzanmehr H; Dasanu CA; Dawson N; Wartofsky L
    Thyroid; 2008 Jul; 18(7):809-12. PubMed ID: 18631016
    [No Abstract]   [Full Text] [Related]  

  • 63. Kidney cancer: TKIs associated with stroke risk.
    Fenner A
    Nat Rev Urol; 2015 Nov; 12(11):597. PubMed ID: 26502989
    [No Abstract]   [Full Text] [Related]  

  • 64. Fatal liver failure in a patient treated with sunitinib for renal cell carcinoma.
    Mermershtain W; Lazarev I; Shani-Shrem N; Ariad S
    Clin Genitourin Cancer; 2013 Mar; 11(1):70-2. PubMed ID: 23063577
    [No Abstract]   [Full Text] [Related]  

  • 65. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
    Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
    Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Sunitinib and hypothyroidism.
    Wolter P; Dumez H; Schöffski P
    N Engl J Med; 2007 Apr; 356(15):1580; author reply 1580-1. PubMed ID: 17429091
    [No Abstract]   [Full Text] [Related]  

  • 67. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
    Santoni M; Conti A; Massari F; Arnaldi G; Iacovelli R; Rizzo M; De Giorgi U; Trementino L; Procopio G; Tortora G; Cascinu S
    Int J Cancer; 2015 Jan; 136(1):1-10. PubMed ID: 24415642
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Subacute cutaneous lupus erythematosus induced by the new multikinase inhibitor pazopanib.
    Casado-Verrier B; Pérez-Santos S; Delgado-Mucientes C; Beato-Merino M
    Br J Dermatol; 2014 Dec; 171(6):1559-61. PubMed ID: 24909204
    [No Abstract]   [Full Text] [Related]  

  • 69. Systemic treatment options for untreated patients with metastatic clear cell renal cancer.
    Molina AM; Motzer RJ; Heng DY
    Semin Oncol; 2013 Aug; 40(4):436-43. PubMed ID: 23972707
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib.
    Chorianopoulos E; Jäger D; Katus HA; Frey N
    Clin Res Cardiol; 2007 Nov; 96(11):829-30. PubMed ID: 17694380
    [No Abstract]   [Full Text] [Related]  

  • 71. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.
    Nicholaou T; Wong R; Davis ID
    Lancet; 2007 Jun; 369(9577):1923-4. PubMed ID: 17560435
    [No Abstract]   [Full Text] [Related]  

  • 72. Pazopanib versus sunitinib in renal cancer.
    Casper J; Schumann-Binarsch S; Köhne CH
    N Engl J Med; 2013 Nov; 369(20):1969. PubMed ID: 24224638
    [No Abstract]   [Full Text] [Related]  

  • 73. Pazopanib versus sunitinib in renal cancer.
    Wittes J
    N Engl J Med; 2013 Nov; 369(20):1969. PubMed ID: 24224637
    [No Abstract]   [Full Text] [Related]  

  • 74. Pazopanib versus sunitinib in renal cancer.
    Ramaekers R; Tharnish M; Copur MS
    N Engl J Med; 2013 Nov; 369(20):1968-9. PubMed ID: 24224636
    [No Abstract]   [Full Text] [Related]  

  • 75. Pazopanib versus sunitinib in renal cancer.
    Motzer RJ; McCann L; Deen K
    N Engl J Med; 2013 Nov; 369(20):1970. PubMed ID: 24224635
    [No Abstract]   [Full Text] [Related]  

  • 76. Pazopanib- and bevacizumab-induced reversible heart failure in a patient with metastatic renal cell carcinoma: A case report.
    Abdallah AO; Vallurupalli S; Kunthur A
    J Oncol Pharm Pract; 2016 Jun; 22(3):561-5. PubMed ID: 25956420
    [No Abstract]   [Full Text] [Related]  

  • 77. The Authors Respond.
    Hansen RN; Hackshaw MD; Sullivan SD; Ramsey SD
    J Manag Care Spec Pharm; 2015 Sep; 21(9):844. PubMed ID: 26536677
    [No Abstract]   [Full Text] [Related]  

  • 78. Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
    Sun M; Trinh QD; Perrotte P; Karakiewicz PI
    Eur Urol; 2014 May; 65(5):1014-5. PubMed ID: 24646500
    [No Abstract]   [Full Text] [Related]  

  • 79. Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
    Ouzaid I; Rini B
    Eur Urol; 2014 Mar; 65(3):667-8. PubMed ID: 24484761
    [No Abstract]   [Full Text] [Related]  

  • 80. The Authors Respond.
    Delea TE; Amdahl J; Diaz J; Nakhaipour HR; El Khoury MH
    J Manag Care Spec Pharm; 2015 Sep; 21(9):836-40. PubMed ID: 26536676
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.